Carlsbad, CA - October 25, 2006 - Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, is developing a monoclonal antibody inhibiting IL-2 signaling as potential novel immunosuppressant. Preclinical data on the compound, designated MT204, were now published online in the journal Molecular Immunology (1).
